Characteristics of study population.

<p>Abbreviations: CVD, cardiovascular disease; BP, blood pressure; iPTH, intact parathyroid hormone; Ca, calcium; P, phosphate; ABI, ankle-brachial index; RAS, renin-angiotensin system.</p><p>Characteristics of study population.</p

Cox proportional hazards regression analysis for cardiovascular mortality.

<p>Abbreviation: CVD, cardiovascular disease; BP, blood pressure; RAS, renin-angiotensin system; PAOD, iPTH, intact parathyroid hormone; Ca, calcium; P, phosphate; peripheral arterial occlusion disease.</p><p>Cox proportional hazards regression analysis for cardiovascular mortality.</p

Kaplan—Meier survival curves.

<p>Probabilities of (A) overall survival with log-rank test: χ² = 60.89; <i>P</i> ≤ 0.001 in the four groups and χ² = 2.02; <i>P</i> = 0.364 in the three PAOD groups. (B) Cardiovascular survival with log-rank test: χ² = 45.24; <i>P</i> ≤ 0.001 in the four groups and χ² = 0.69; <i>P</i> = 0.708 in the three PAOD groups.</p

Cox proportional hazards regression analysis for all-cause mortality.

<p>Abbreviation: CVD, cardiovascular disease; BP, blood pressure; RAS, renin-angiotensin system; iPTH, intact parathyroid hormone; Ca, calcium; P, phosphate; PAOD, peripheral arterial occlusion disease.</p><p>Cox proportional hazards regression analysis for all-cause mortality.</p

Probabilities of overall survival according to dominance side of ABI value.

<p>(A) in all patients with log-rank test: χ² = 1.32; <i>P</i> = 0.249; (B) in patients without PAOD with log-rank test: χ² = 3.47; <i>P</i> = 0.062; (C) in patients with PAOD with log-rank test: χ² = 0.20; <i>P</i> = 0.651.</p

Characteristics of patients at inclusion according to the location of PAOD.

<p>Abbreviations: CVD, cardiovascular disease; BP, blood pressure; iPTH, intact parathyroid hormone; Ca, calcium; P, phosphate; RAS, renin-angiotensin system</p><p>*Comparison between all four groups</p><p>^# Comparison between all groups except non-PAOD group.</p><p>Characteristics of patients at inclusion according to the location of PAOD.</p

Demographic and baseline characteristics of study population (N = 202).

Demographic and baseline characteristics of study population (N = 202).</p

Fig 3 -

Changes in (A) ferritin and (B) TSAT from M0 to EOT according to different baselines of ferritin (500 ng/mL) and TSAT (<30%, ≥30%). The trend of continuous data was calculated by a linear regression. Abbreviations: TSAT, transferrin saturation; M0, baseline; EOT, end-of-treatment. The values were expressed as mean and standard error (SE).</p

Changes in serum phosphorus, hemoglobin, iron-related parameters, calcium and iPTH (N = 197).

Changes in serum phosphorus, hemoglobin, iron-related parameters, calcium and iPTH (N = 197).</p

Changes of iPTH levels after stratified by concomitant vitamin D treatment.

(DOCX)</p